Area of research
Virology · Infectious Diseases
Research interest
Research interests include HIV Research and Treatment, HIV/AIDS drug development and treatment, vaccines and immunoinformatics approaches, and Monoclonal and Polyclonal Antibodies Research.
Bayesian estimation of HIV acquisition dates for prevention trials
Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial
Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings
Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials
Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features
Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials
TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine